By screening potential monoclonal antibody (mAb)-based drugs solely on a measure of their colloidal stability, scientists may be able to weed out mAbs that do not respond efficiently in solution early in the drug discovery process, according to a new study.
This finding could enable researchers to overcome a major hurdle to drug development by identifying promising mAb-based therapies, which must be administered via injection, but often lack the properties necessary to succeed as solutions.
“Therapeutic antibodies that neutralise pathogens are a promising way to treat infectious disease,” said Jonathan Kingsbury, study author. “Selection of well-behaved antibodies with molecular properties that enable streamlined manufacturing, scale-up, and subcutaneous delivery is key for rapid development, particularly during a pandemic response.”
The paper says mAb solution behaviour can be predicted with 90% accuracy based on its diffusion interaction parameter.
